Zylberberg H, Pol S
Service d'Hépatologie, Hôpital Necker, Paris, France.
Clin Infect Dis. 1996 Nov;23(5):1117-25. doi: 10.1093/clinids/23.5.1117.
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) share the same routes of transmission, which explains the high rate of HCV and HIV coinfection (approximately 9%). HIV/HCV coinfection leads to high rates of indeterminate recombinant immunoblot assay patterns and seroreversion; high levels of viral replication; and a more severe histopathologic course. By contrast, HCV infection does not seem to accelerate the progression of HIV infection. Interferon alpha (IFN-alpha) in coinfected patients leads to a similar rate of primary responses, but sustained responses are less frequent. The potential severity of hepatitis C virus infection evidences the need for early diagnosis. Liver biopsy should be performed for all HCV RNA-positive patients in order to evaluate the activity of the liver disease. Given the poor efficiency of IFN-alpha in terms of sustained response in HIV-infected patients, reinforced therapeutic procedures (long-term administration of IFN-alpha or combined ribavirin/IFN-alpha) should be proposed, at least for those patients with severe liver disease.
丙型肝炎病毒(HCV)和人类免疫缺陷病毒(HIV)具有相同的传播途径,这解释了HCV与HIV合并感染的高发生率(约9%)。HIV/HCV合并感染会导致不确定的重组免疫印迹试验模式和血清学逆转的高发生率;高水平的病毒复制;以及更严重的组织病理学病程。相比之下,HCV感染似乎不会加速HIV感染的进展。合并感染患者使用α干扰素(IFN-α)会产生相似的初始反应率,但持续反应较少见。丙型肝炎病毒感染的潜在严重性表明需要早期诊断。应对所有HCV RNA阳性患者进行肝活检,以评估肝病的活动情况。鉴于IFN-α对HIV感染患者的持续反应效率较低,至少对于那些患有严重肝病的患者,应建议采用强化治疗程序(长期使用IFN-α或联合使用利巴韦林/IFN-α)。